ASX:AT1

Atomo Diagnostics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive AT1 News and Ratings via Email

Sign-up to receive the latest news and ratings for Atomo Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


About Atomo Diagnostics

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection. The company has operations in Europe, Asia, Africa, and Central and South America. Atomo Diagnostics Limited was founded in 2010 and is headquartered in Leichhardt, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Atomo Diagnostics (ASX:AT1) Frequently Asked Questions

What stocks does MarketBeat like better than Atomo Diagnostics?

Wall Street analysts have given Atomo Diagnostics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Atomo Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Atomo Diagnostics' key executives?

Atomo Diagnostics' management team includes the following people:
  • Mr. John Michael Kelly, Founder, CEO, MD & Director
  • Mr. William Edward Souter BCom, LLB (Adel), IPAA, Chief Financial Officer
  • Mr. Mark Smith, Chief Operating Officer
  • Mr. Fabio Baglioni, Chief Commercial Officer
  • Ms. Gillian Maria Nairn, Company Sec.

Who are some of Atomo Diagnostics' key competitors?

What is Atomo Diagnostics' stock symbol?

Atomo Diagnostics trades on the ASX under the ticker symbol "AT1."

How much money does Atomo Diagnostics make?

Atomo Diagnostics has a market capitalization of $0.00 and generates $9.01 million in revenue each year.

What is Atomo Diagnostics' official website?

The official website for Atomo Diagnostics is atomodiagnostics.com.

How can I contact Atomo Diagnostics?

The company can be reached via phone at 61 2 9099 4750.


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.